Bn42083 A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis
Posted Date: Feb 15, 2021
- Investigator: Aram Zabeti
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
The primary efficacy objective is to demonstrate the superiority of a higher dose of ocrelizumab over the approved dose of ocrelizumab as assessed by risk reduction in cCDP sustained for at least 12 weeks.
Criteria:
Participant Must Be Between 18-55 That Has Been Diagnosed With Primary Progressive Multiple Sclerosis (Ppms) And Be Neurologically Stable For At Least 30 Days Prior To Randomization And Baseline Assessments.
Keywords:
Primary Progressive Multiple Sclerosis, Neurology, Ocrelizumab
For More Information:
Tiffany Rupert
513-558-0269
tiffany.rupert@uc.edu